EVS Glaucoma Therapeutics Closes Investment with CIT GAP Funds

Funding Rounds

▤ Summary

EVS Glaucoma Therapeutics, a Herndon-based spinout of Euclid Vision Systems that develops a sustained delivery system for glaucoma medication, closed an investment with the Center for Innovative Technology’s GAP Funds.The amount of the funding was not disclosed.The company intends to use the funds to pursue further development of its delivery system.Led by Michael Ross, CEO, EGT develops an implantable, bio-degradable, collagen-based drug delivery system for Latanoprost, the leading prescribed glaucoma medication.FinSMEs 11/09/2013

$ Funding

$
Amount - Total raised
□
Date September 11, 2013 Announcement date
◎
Investors CIT GAP Funds Lead investors
▥
Company - Funded company

▥ Classifications

industries
Real Estate
applications
Web Shopping

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies